Reza Yavari
Endocrinology, Diabetes & Metabolism · Branford, CTNPI 1053477703
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,378 and has fallen 56.8% since, to $1,027 in 2025.
Across 404 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Abbott$2K
- Insulet Corporation$968
- Sanofi-aventis U.S. LLC$933
- Corcept Therapeutics$530
- plus $2K from 16 others
What the payments were for
- Food & beverage$8,707100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 117 | $1,674 |
| Lilly USA, LLC | 78 | $1,512 |
| Abbott | 26 | $1,508 |
| Insulet Corporation | 53 | $968 |
| Sanofi-aventis U.S. LLC | 32 | $933 |
| Corcept Therapeutics | 21 | $530 |
| Tandem Diabetes Care, Inc. | 7 | $369 |
| Antares Pharma, Inc. | 16 | $291 |
| AbbVie | 15 | $285 |
| Boehringer Ingelheim | 8 | $146 |
| IBSA Pharma Inc. | 6 | $105 |
| AstraZeneca(2 entities) | 5 | $90 |
| Halozyme Inc | 3 | $53 |
| Merck | 3 | $47 |
| Cequr Corporation | 2 | $42 |
| Dexcom, Inc. | 2 | $40 |
| Amgen | 2 | $40 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Aytu Biopharma, Inc. | 2 | $29 |
| Nalpropion Pharmaceuticals LLC | 2 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$732
- Omnipod$202
- Korlym$125
- t-slim insulin pump$121
- SOLIQUA 100/33$121
- Ozempic$120
- Saxenda$120
How this compares
$8,741 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 147 | $180,144 |
| OzempicSemaglutide | 69 | $102,485 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $41,223 |
| JardianceEmpagliflozin | 30 | $35,347 |
| ProliaDenosumab | 19 | $32,882 |
| TrulicityDulaglutide | 18 | $22,151 |
| JanuviaSitagliptin Phosphate | 19 | $20,488 |
| LyumjevInsulin Lispro-Aabc | 19 | $16,125 |
| TradjentaLinagliptin | 15 | $15,198 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 21 | $13,116 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,870 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $5,202 |
| TirosintLevothyroxine Sodium | 12 | $4,004 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $3,953 |
| Testosterone | 36 | $2,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev | $1,512 | $218,420184 claims |
| Novo NordiskOzempic | $1,674 | $102,48569 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $146 | $63,66166 claims |
| AmgenProlia | $40 | $32,88219 claims |
| MerckJanuvia | $47 | $20,48819 claims |
| IBSA Pharma Inc.Tirosint | $105 | $4,00412 claims |
| AbbVieArmour Thyroid | $285 | $50711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Branford
- Jean HenryBranford$7K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.